You are here:

Cambium Dry Eye Study Results Exceed Expectations

Study Evaluated Standardized, Novel, Enriched Biologic for Ocular Graft-vs.-Host Disease ATLANTA, GA – March 5, 2020 – Cambium Medical Technologies, a clinical stage company developing novel processed platelets for therapeutic applications, today announced receipt of results from a Phase I/II study of its Elate Ocular® topical fibrinogen-depleted human platelet lysate.  The  biologic was tested among ...
Read more

Cambium Announces Orphan Drug Designation for Dry Eye Indication

First Biologic to Receive Orphan Drug Status for Ocular Graft-Vs.-Host Disease Dry Eye ATLANTA, GA –Feb. 26, 2020 – Cambium Medical Technologies (Cambium), a clinical stage company developing novel processed platelets for therapeutic applications, announced today that the U.S. Food & Drug Administration (FDA) has granted the company orphan drug designation for its fibrinogen-depleted human ...
Read more

Cambium Enrolls Final Patient in Phase I/II Dry Eye Study

Study Evaluating Standardized, Novel, Enriched, Allogeneic Serum Drop for Ocular Graft-vs.-Host Disease ATLANTA, GA – Feb. 20, 2020 – Cambium Medical Technologies (“Cambium”), a clinical stage company developing novel processed platelets for various therapeutic applications, announced the final patient was enrolled in Dec. 2019 for its Elate Ocular® topical fibrinogen-depleted human platelet lysate biologic in ...
Read more

Cambium Enrolls First Patient in Phase I/II Study to Evaluate Platelet Lysate Biologic for Graft-vs.-Host Disease Dry Eye

ATLANTA, GA – June 15, 2018 – Cambium Medical Technologies (“Cambium”), a clinical stage company, announced today first patient enrollment for its Elate Ocular™ topical fibrinogen-depleted human platelet lysate biologic in a randomized, multicenter, double-masked placebo-controlled parallel Phase I/II study. The study is designed to determine safety and exploratory efficacy in patients with dry eye ...
Read more

FDA Notifies Cambium Phase I/II Dry Eye Study Can Proceed

Study for Graft vs. Host Disease Dry Eye to Begin Late 2017/Early 2018 ATLANTA, GA – September 29, 2017 – Cambium Medical Technologies (“Cambium”), a clinical stage company, announced today that the U.S. Food & Drug Administration (“FDA”) notified Cambium on September 22 it has completed review of Cambium’s Investigational New Drug Application (IND) submitted ...
Read more

Cambium Medical Technologies Announces Major Development And Collaboration Agreement with Pacific Rim Partner

Gwowei Technology Company, Ltd., Taiwan, to Join Cambium in Development and Commercialization of Certain Human Platelet Derived Research and Therapeutic Products ATLANTA, GA – May 19, 2014 – Cambium Medical Technologies (“Cambium” or “the Company’) announced today the signing of a Joint Development and Collaboration Agreement (“JDCA”) with a U.S. subsidiary of Gwowei Technology Company ...
Read more